Back to All Peptides
Recovery & HealingImmune Supportinjectable

ARA-290 (Cibinetide)

Non-erythropoietic EPO derivative targeting neuropathic pain and repair.

Human clinical evidenceStudied in one or more human clinical trials, but not FDA-approved for this use. Evidence quality and trial size vary — see sources.

For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.

About ARA-290 (Cibinetide)

ARA-290 (Cibinetide) is an 11-amino-acid peptide derived from the tertiary structure of erythropoietin that activates the innate repair receptor without EPO's effects on red blood cell production. Research focuses on reducing neuropathic pain and inflammation and promoting tissue repair, particularly in conditions such as sarcoidosis-associated small-fiber neuropathy.

Key Benefits

  • Targets the innate repair receptor
  • Reduces neuropathic pain
  • Modulates inflammation
  • No effect on red blood cell production

Set a goal (top of the page) to see how ARA-290 (Cibinetide) scores against it, and what the better-evidenced alternatives are.

Category Ratings

Muscle & Strength
N/A
Fat Loss
N/A
Recovery
Good
Skin & Anti-Aging
N/A
Sleep
N/A
Cognitive
Minimal
Immune
Good
Longevity
Mild
Bone & Hormonal
N/A

How to Take

Injection

Subcutaneous injection, typically in the morning

Common Side Effects

  • Injection site reactions
  • Mild headache
  • Fatigue

Legal & Regulatory Status

Investigational — studied in Phase 2 trials (as cibinetide/ARA-290) for neuropathic pain and sarcoidosis. Not FDA-approved.

Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.

Research & Sources

Human clinical evidenceStudied in one or more human clinical trials, but not FDA-approved for this use. Evidence quality and trial size vary — see sources.

Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.

ARA-290 (Cibinetide)

Prices at quality-checked sources · as of August 2026 (3 weeks ago)

Observed on each vendor’s public listing — see how these sources are vetted. Peptide Concierge doesn’t sell peptides and isn’t affiliated with any vendor; confirm current pricing at the source.

CategoryRecovery
Formsinjectable

Builds a working set shared across the stack builder, calculator, scheduler and compare.